HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $11 price target.
Stocks · News reference
Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share